Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

GLP-1 drugs have transformed lives, for good and bad. Here's what happens to your heart, liver, skin, and more ...

Eamon Quinn: 'Prosperity across the island is tied to tech titans such as Apple, Intel and Microsoft, but is also linked to ...

Several leading Indian drugmakers have already secured regulatory approval or recommendations to produce and market generic ...

Novo Nordisk A/S remains a Buy despite CagriSema setback; Eli Lilly and Company remains a Hold on valuation. Click for this ...

Novo Nordisk (NVO) stock is in focus as a study estimates generic semaglutide (Ozempic/Wegovy) could cost under $3/month as its patents expire this year. Read more here.

New research has found that people taking medications such as Mounjaro or Wegovy for weight loss purposes may regain the majority of the weight they lost when they stop taking it. The jabs, also known ...

A new study has looked into what happens when people stop taking weight-loss jabs ...

Aspen Pharmacare aims to secure sub‑Saharan African approval for Eli Lilly's blockbuster weight‑loss drug Mounjaro as early ...